ArticleProceedings of the National Academy of Sciences of the United States of America2021
High-throughput functional variant screens via in vivo production of single-stranded DNA.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 104 citations in OpenAlex.
- Discovery and engineering of retrons for precise genome editing.Nature biotechnology · 2026Article
- Genome editing of phylogenetically distinct bacteria using cross-species retron-mediated recombineering.Nature biotechnology · 2026Article
- RNA-templated diversity generation via reverse transcription and homologous recombination: an evolutionary hypothesis.Theory in biosciences = Theorie in den Biowissenschaften · 2026Article
- Diversity-generating retroelements for programmable targeted hypermutagenesis.Nature biotechnology · 2026Article
- Article
- CRISPR-DNA Polymerase Assisted Targeted Mutagenesis for Regulable Laboratory Evolution.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Precise virulence inactivation using a CRISPR-associated transposase for combating Enterobacteriaceae gut pathogens.Nature biomedical engineering · 2025Article
- Structurally related phage helicases trigger type III-A3 retron-mediated anti-phage defense across diverse tailed phage families.Nucleic acids research · 2025Article
- Endogenous fine-mapping and prioritization of functional regulatory elements in complex genetic loci.Cell genomics · 2025Article
- Scaling DNA engineering.Trends in biotechnology · 2025Review
- New retron systems from environmental bacteria identify triggers of anti-phage defense and expand tools for genome editing.PLoS biology · 2025Article
- Phage therapy and its role in cancer treatment and control.Folia microbiologica · 2025Review
- Structural basis of the RNA-mediated Retron-Eco2 oligomerization.Cell discovery · 2025Article
- Disassembly activates Retron-Septu for antiphage defense.Science (New York, N.Y.) · 2025Article
- Continuous multiplexed phage genome editing using recombitrons.Nature biotechnology · 2025Article
- Review
- An experimental census of retrons for DNA production and genome editing.Nature biotechnology · 2025Article
- An evolved, orthogonal ssDNA generator for targeted hypermutation of multiple genomic loci.Nucleic acids research · 2025Article
- High throughput variant libraries and machine learning yield design rules for retron gene editors.Nucleic acids research · 2025Article
- Reducing competition between msd and genomic DNA improves retron editing efficiency.EMBO reports · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Creating and characterizing individual genetic variants remains limited in scale, compared to the tremendous variation both existing in nature and envisioned by genome engineers. Here we introduce retron library recombineering (RLR), a methodology for high-throughput functional screens that surpasses the scale and specificity of CRISPR-Cas methods. We use the targeted reverse-transcription activity of retrons to produce single-stranded DNA (ssDNA) in vivo, incorporating edits at >90% efficiency and enabling multiplexed applications. RLR simultaneously introduces many genomic variants, producing pooled and barcoded variant libraries addressable by targeted deep sequencing. We use RLR for pooled phenotyping of synthesized antibiotic resistance alleles, demonstrating quantitative measurement of relative growth rates. We also perform RLR using the sheared genomic DNA of an evolved bacterium, experimentally querying millions of sequences for causal variants, demonstrating that RLR is uniquely suited to utilize large pools of natural variation. Using ssDNA produced in vivo for pooled experiments presents avenues for exploring variation across the genome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.